ACTG1 promotes breast cancer aggressiveness and confers ribociclib resistance by deubiquitinating HSPA8 through UCHL3

ACTG1 通过 UCHL3 途径使 HSPA8 去泛素化,从而促进乳腺癌的侵袭性并赋予其对瑞博西尼的耐药性。

阅读:1

Abstract

In this study, we examined the biological significance of the actin gamma 1 (ACTG1)-UCHL3–HSPA8 axis in breast cancer. Through bioinformatic analysis, we recognized ACTG1 as a potential oncogenic factor in BRCA. By exploiting qRT-qPCR and Western blot analysis, we assessed the expression of ACTG1 and explored its impact on cellular proliferation, migration, and invasion. Our findings suggest that ACTG1 exerts its oncogenic effects in breast cancer cells through the EMT signaling pathway. By mining the BIOGRID database, we identified potential downstream regulatory genes; and co-immunoprecipitation assays confirmed protein interactions between ACTG1 and HSPA8. We also observed that ACTG1 promoted breast cancer cell proliferation, invasion, and migration via its interaction with HSPA8. Importantly, our study elucidated the facilitation by UCHL3 of HSPA8 deubiquitination by ACTG1. In conclusion, our study revealed a key role played by the ACTG1–UCHL3–HSPA8 axis in driving breast cancer progression as well as the role of ribociclib resistance. Our findings provide compelling evidence for the therapeutic potential of targeting this axis in breast cancer treatment strategies. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s13402-025-01144-8.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。